Athira Pharma, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington. Show more

Location: 18706 North Creek Parkway, Bothell, WA, 98011, United States | Website: https://www.athira.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

15.54M

52 Wk Range

$0.22 - $0.83

Previous Close

$0.39

Open

$0.38

Volume

67,818

Day Range

$0.38 - $0.39

Enterprise Value

-13.27M

Cash

29.82M

Avg Qtr Burn

-17.68M

Insider Ownership

8.70%

Institutional Own.

45.05%

Qtr Updated

06/30/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Fosgonimeton (ATH-1017) Details Parkinson's disease, Dementia	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ATH-1105 Details Amyotrophic lateral sclerosis	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Fosgonimeton (ATH-1017) Details Alzheimer's disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.